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Paraneoplastic neurological syndromeA high seroprevalence of Yo antibodies targeting cerebellar Purkinje cells was recently reported in children with
attention deﬁcit/hyperactivity disorder (ADHD). We investigated the presence of 8 paraneoplastic neurological
syndrome (PNS)-associated antibodies including anti-Yo in 169 adult ADHD patients. No associations between
ADHD and serum Yo antibodies or other antibodies associated with PNS were found. However, 10 out of 48
ADHD patient sera analyzed by immunoﬂuorescence presented antibodies targeting cerebellar Purkinje cells.
This reactivity probably represents the presence of low levels of antibodies against multiple cellular hitherto
unknown antigens with little to no clinical signiﬁcance.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Attention-deﬁcit/hyperactivity disorder (ADHD) is a neuropsychiatric
disorder characterizedby inattention andhyperactive/impulsive behavior
and affects approximately 5–8% of children (Polanczyk et al., 2007). The
disorder results in educational, occupational and social impairments,
and is often associated with other psychiatric comorbidities including
signiﬁcant depression, anxiety, oppositional-deﬁant disorder and sub-
stance use disorder (Halmøy et al., 2009). ADHD often persists into
adulthood and the average prevalence is estimated to be between
2.5% and 4.9% in the adult population (Simon et al., 2009; Kessler
et al., 2006). Both genetic and environmental risk factors have been
proposed, but the precise etiology of ADHD is still largely unknown.
Autoantibodies affecting the central nervous system have been sug-
gested to play a role in neuropsychiatric disorders including autism,
schizophrenia and limbic encephalitis (Margari et al., 2013; Moscato
et al., 2010; Braunschweig and Van de Water, 2012; Ezeoke et al., 2013;
Leypoldt et al., 2015). For a review see Najjar et al. (2013). Laadhar et al.
detected neuronal antibodies in sera from 20 out of 103 Tunisian
psychiatric patients, including 5 patients with the paraneoplastic
neurological syndromes (PNS) associated antibodies anti-Ri or anti-tics and Molecular Medicine,
Haukanes).
. This is an open access article underYo. Antibodies were not detected in any of the 41 control subjects
(Laadhar et al., 2015). However, Dahm et al. recently reported antibod-
ies against brain antigens with comparable seroprevalence in both
healthy subjects (N = 1703) and patients with neuropsychiatric
disorders (N = 2533), and questioned their clinical importance
(Dahm et al., 2014).
An Italian study has suggested a high prevalence of cerebellar
Purkinje cell speciﬁc antibodies in children with ADHD (Passarelli
et al., 2013). Yo antibodies were detected in the serum of 26 out of 30
ADHD children, and in none of the 27 sex- and age-matched healthy
controls. In addition, 5 of 19 non-ADHD children with oppositional-
deﬁant or conduct disorder and dyslexia also had anti-Yo in their sera.
These results are unexpected as the presence of neuronal antibodies
like anti-Yo, anti-Ri, anti-Hu, anti-CRMP5, anti-Ma1/2, and anti-
amphiphysin are associated with PNS, and indicate an underlying
cancer (Storstein and Vedeler, 2007). For example, anti-Yo normally
causes paraneoplastic cerebellar degeneration (PCD) in women with
breast or ovarian cancer. However, cerebellar dysfunction has also
been suspected in ADHD (S. Mackie et al. 2007).
The study by Passarelli et al. (2013) suggests that Yo antibodies may
be associated with ADHD and without cancer. We therefore performed
a similar study on a larger sample (N= 169) of Norwegian adult ADHD
patients. We were not able to conﬁrm an association between ADHD
and neuronal antibodies related to PNS, in accordance with the study
by Dahm et al. (2014) on other psychiatric phenotypes.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical characteristics of ADHD patients and control subjects.
ADHD patients Controls p-Valuea
N 169 56
Females, % (N) 49.7 (84) 55.4 (31) 0.538
Age range, years 17–60 18–74
Age, years: mean ± SD 33.0 ± 10.1 34.9 ± 15.5 0.385b
ADHD treatment in childhood, % (N)c 11.3 (18/159) 0 (0/56) 0.004
Self-reported morbidity, % (N)c
Signiﬁcant depression/anxiety 63.5 (101/159) 1.8 (1/56) b0.001
Bipolar Disorder 9.2 (14/153) 0 (0/56) 0.024
Dyslexia 49.0 (77/157) 0 (0/56) b 0.001
Intellectual Disability 2.5 (4/159) 0 (0/56) 0.575
Epilepsy 4.4 (7/160) 0 (0/56) 0.194
Migraine 27.2 (43/158) 14.3 (8/56) 0.067
ADHD variables, mean ± SD (N)d
ASRS inattentive score 23.7 ± 6.4 (157) 11.3 ± 4.4 (52) b0.001b
ASRS hyperactive/impulsive
score 21.8 ± 6.7 (159) 8.9 ± 4.3 (53) b0.001b
ASRS total score 45.4 ± 11.8 (156) 20.2 ± 8.0 (52) b0.001b
WURS total 57.7 ± 16.7 (143) 12.0 ± 8.3 (54) b0.001b
ASRS subtype, % (N)
Combined 51.9 (81) 1.9 (1)
Hyperactive/Impulsive 5.1 (8) 0 (0)
Inattentive 21.2 (33) 1.9 (1)
Subthreshold 21.8 (34) 96.2(50)
Sum (156) (52)
ASRS = Adult ADHD Self-Report Scale, WURS =Wender Utah Rating Scale.
a Fisher's exact test with 2-sided p-values if not otherwise stated.
b T-test with 2-sided p-values.
c Positive/case numbers. The varying case numbers are due to blank responses on the
questionnaires.
d Case numbers.
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2.1. Subjects
Adult Norwegian ADHD patients (N = 169, age 17–60 years) were
included in this study. Adult ADHD is deﬁned as ADHD that has
appeared before age 12 and persists beyond 17 years of age (DSM-5,
American Psychiatric Association, 2013). All patients were evaluated
by experienced clinicians and diagnosed with persistent ADHD accord-
ing to DSM-IV criteria (American Psychiatric Association, 2000) as
previously described (Johansson et al., 2008; Halmøy et al., 2009;
Haavik et al., 2010). Furthermore, current and past symptom scores
were collected using the auto-questionnaires ASRS (Adult ADHD
Self-Report Scale (Kessler et al., 2005) andWURS (Wender Utah Rating
Scale (Ward et al., 1993)), in addition to a detailed questionnaire on
psychiatric comorbidity and history. The ADHD subtypes were deﬁned
by 21 or more points on one or both of the ASRS subscales. 51.9% of
the ADHD patients (N = 81) presented the combined subtype, 21.2%
(N = 33) were predominantly inattentive, and were 5.1% (N = 8)
predominantly hyperactive/impulsive. The remaining patients were
subthreshold.
Healthy controls were recruited from the Medical Birth Registry of
Norway (MBRN) database by invitation letters. As for the ADHD
patients, all controls completed self-report questionnaires in the form
of the ASRS, WURS and questionnaire on psychiatric comorbidity and
history. Fifty-six responders aged 18–74 years, and from whom we
received completed self-report questionnaires and biological samples,
were selected.
Clinical characteristics of the ADHD patients and control subjects are
summarized in Table 1. The age and gender distributions were fairly
equal between the ADHD patients and the controls. The mean age of
the ADHD patients was 33.0 years (SD 10.1) versus 34.9 years (SD
15.5) for the control group, and the proportion of females was 49.7%
in the ADHD group and 55.4% in the control group.
Sera frompatients with PNSwith Yo or Hu antibodieswere obtained
from the Neurology research laboratory, HaukelandUniversity Hospital,
Bergen, Norway.
The project was approved by the Regional Committee for Medical
Research Ethics ofWesternNorway (IRB 00001872; 2013/543).Written
informed consent was obtained from all participants in the study.
2.2. Detection of autoantibodies
2.2.1. Immunoblotting
The 169 ADHD sera were tested for antibodies by two immunoblot
protocols, the PNS+2 LineBlot fromRavoDiagnostikaGmbH(Freiburg,
Germany) and the Neuronal Antigens Proﬁle 2 from Euroimmun
Medizinische Labordiagnostika AG (Lübeck, Germany). Sera from PNS
patients with Yo and Hu antibodies, in addition to Hu positive Proﬁle
2 Kit control serum (Euroimmun), were used as positive controls.
Sera from the 56 normal controls were also analyzed by the Neuronal
Antigens Proﬁle 2 strips. Line blots with no added serum samples
were used as negative controls.
Nitrocellulose test strips (PNS + 2 Line Blot from Ravo Diagnostika
coated with the recombinant antigens HuD, CDR2/Yo, Ri (Nova1),
CRMP5, amphiphysin, Ma1/Ma2, SOX1 and GAD65 were incubated
with a 1:2000 dilution of patient- and control sera according to the
manufacturer's instructions. Bound antibodies were detected by
alkaline phosphate conjugated to anti-human IgG using BCIP/NBT
(5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium) as
substrate. The intensity of the bands was evaluated manually. A distinct
band corresponding to the actual position of the antigen in the line blot
was considered as a positive signal.
Euroline line blots (Neuronal Antigens Proﬁle 2 from Euroimmun
Medizinische Labordiagnostika AG) coated with recombinant
amphiphysin, CRMP5, PNMA2 (Ma2/Ta), Ri (Nova1), CDR2/Yo, andHuD were utilized according to the protocol provided by the supplier.
Patient- and control sera were diluted 1:101, added to the line blots
and assayed in a EuroBlotMaster 44 blot processor. Incubated line
blots were scanned and automatically evaluated with the EuroLineScan
software (EuroLineScanV3.4.4). All sera were analyzed in duplicate.
2.2.2. Indirect immunoﬂuorescence
Rat cerebellum was ﬁxed by immersion in 4% paraformaldehyde in
0.1 M phosphate buffer for 48 h, rinsed in 0.1 M phosphate buffer,
cryoprotected by 20% sucrose in 0.1 M phosphate buffer and snap-
frozen. Cryostat sections (8 μm thick) of ﬁxed tissue on microscope
slides were incubated with sera diluted 1:100 and 1:500 in PBT (PBS
with 1% BSA and 0.2% Triton X) at 4 °C overnight in a moist chamber.
The slides were subsequently washed with PBT and incubated with
Alexa Fluor 488 goat anti-human IgG (Molecular probes, Eugene, OR,
USA) diluted 1:100 in PBT, for 90 min at room temperature. Finally,
the slides were washed in PBS, covered and examined by ﬂuorescence
microscopy (Leica DM IL, Leica Microsystems Ltd., Heerbrugg,
Switzerland, or Nikon Eclipse E800, Nikon Corporation Instruments
Company).
Euroimmun Indirect Immunoﬂuorescence test (Euroimmun #FA
1111–monkey cerebellum) was performed according to the
manufacturer's protocol (Euroimmun Medizinische Labordiagnostika
AG) to detect serum antibodies. Frozen sections of primate cerebellum
were incubated for 30 min at room temperature with a 1:10 dilution
of patient- or control serum in PBS-Tween. Attached antibodies were
stained with ﬂuorescein-labeled anti-human IgA/G/M antibodies. The
slides were evaluated using a Nikon Eclipse E800 ﬂuorescence micro-
scope. Sera from PNS patients with Yo and Hu antibodies, in addition
to Yo Ab control (Euroimmun, CA-1113-0101), were used as positive
controls. Sections with no serum samples, but only ﬂuorescein-labeled
anti-human IgA/G/M were used as negative controls.
2.2.3. Cell culture and transfection
HeLa cells (ATCC-CCL-2) were grown in DMEM (Dulbecco's modi-
ﬁed eagle medium), supplemented with 10% FCS (Sigma Aldrich, St.
89B.I. Haukanes et al. / Journal of Neuroimmunology 288 (2015) 87–91Louis, MO, USA), L-glutamine (PAA,M11–004) and Pen Strep (SigmaAl-
drich; P4333). Cells were grown on poly-L-lysine coated glass-
coverslips (10 mm) the day before transfection. cDNA for full-length
CDR2 (Origene, Germany; CDR2 sequence was transferred from vector
RG204900 with C-terminal GFP into vector PS10019 with N-terminal
GFP) or CDR2L (Origene; CDR2L sequence transferred from vector
RC206909 with C-terminal myc-DDK tag into vector PS10010 with C-
terminal GFP) were used to transfect HeLa cells following the standard
protocol for Lipofectamine2000 (Invitrogen Life Technologies, CA,
USA; 11668-019). Transfected HeLa cells were ﬁxed and immunocyto-
chemically labeled with patient sera and antibodies against CDR2 and
CDR2L 24 h after transfection as described elsewhere (Bittins et al.,
2010). All sera and antibodies were diluted in blocking solution (0.2%
gelatin in PBS). Patient sera were diluted 1:100. All samples were pre-
pared in duplets. Secondary antibodies coupled to Alexa Fluor (AF)
594 (Invitrogen; anti-rabbit-AF594 A11012, anti-human-AF594
A11014) were used at a 1:200 dilution. Coverslips were mounted with
ProLong Gold with DAPI (Invitrogen; P36931) and dried overnight.
Imaging of HeLa cells was performedwith a Zeiss AxiovertM200micro-
scope equipped with a Till Photonics Polychrome V monochromator, a
sensicam imago QE CCD camera (PCO) and Till Vision 4.0 software.
2.2.4. Western blot analysis
Rat cerebellum tissue lysates were made using Chemicon Total Pro-
tein Extraction Kit #2140 (Chemicon International, Temecula, CA, USA),
and stored at −80 °C. The protein concentration was determined by
BioRad DC protein assay #500-0111 (Bio-Rad, CA, USA).
Lysates (30 μg) from homogenized rat cerebellar tissue were sub-
jected to 4–12% Bis-Tris precast NuPAGE (Novex by Life, MA, USA;
#NP0323), electroblotted onto nitrocellulose membrane (0.45 μm
pore size; Novex by Life; #LC2001) and incubated overnight at 4 °C
with diluted patient sera (1:100 and 1:500 in 0.05% PBS-Tween and Su-
perBlock Blocking buffer (Thermo Scientiﬁc, MA, USA; #37515)). The
blots were developed using rabbit anti-human horseradish peroxidase
(HRP) conjugated antibody (DAKO, Agilent Technologies, Santa Clara,
CA, USA; #P0212; dilution 1:1000, incubated overnight at 4 °C) and
SuperSignalWest Pico Chemiluminescent Substrate (Thermo Scientiﬁc;
#34080), and read in a Fujiﬁlm LAS-1000 Plus image analyzer
(ImageReader software LAS10000 pro v2.6).
2.3. Statistics
All statistical analyses were performed using IBM SPSS Statistics for
Windows, Version 20, IBM Corp., Armonk, NY, USA.
3. Results
3.1. Immunoblotting
None of the ADHDor control sera reactedwith the PNS+2 Line Blot.
The EuroLineScan software reported several borderline signals
(intensity 6–10) including CDR2/Yo, amphiphysin and/or Ma2 bands
in 9 of the ADHD sera. One of the sera revealed a very weak positive
CDR2/Yo band (intensity 11) as compared to the positive control
bands (intensity 99–134) (data not shown).
3.2. Indirect immunoﬂuorescence
The 10 serum samples that yielded borderline positive antibody
signals and 38 randomly selected ADHD serum samples were further
investigated by indirect immunoﬂuorescence on monkey and rat
cerebellar sections. Ten of the 48 (21%) ADHD sera, of which 7 gave
borderline signals onNeuronal Antigens Proﬁle 2, showedpositive cyto-
plasmic staining of the monkey and rat Purkinje cells. The staining
pattern resembled that seen with Yo antibody positive sera frompatients with PCD (Fig. 1). None of the 48 normal control sera stained
the Purkinje cells.
3.3. Cell culture and transfection
To investigatewhether the cytoplasmic Purkinje cell staining or bor-
derline Neuronal Antigens Proﬁle 2 signals were due to binding to the
Yo antigen (CDR2 and/or CDR2L proteins), we tested the 13 ADHD
sera (10 borderline value at Euroimmun line blot and 3 line blot nega-
tive but immunoﬂuorescence positive sera) on HeLa cells transfected
with either CDR2 or CDR2L. This technique has previously been used
to determine the presence of CDR2 and/or CDR2L antibodies in human
serum samples (Eichler et al., 2013). None of the 13 ADHD patient
sera bound to the transfected CDR2 or CDR2L cells (data not shown).
The anti-Yo positive control serum from a patient with PCD bound to
both the CDR2 and CDR2L transfected cells.
3.4. Western blot analysis
Western blot analysis was performed using 4 of the ADHD patient
sera that stained Purkinje cell cytoplasm by immunoﬂuorescence and
also yielded borderline positive antibody signals revealed by the
Euroimmun line blot. As positive and negative controls we used serum
from a PCD patient with Yo antibodies and only HRP conjugated
antibody without serum, respectively.
The 4 ADHD patient sera reacted against several proteins with
molecular weight (MW) of 10 to 83 kDa in the rat cerebellum extract,
but with no binding to the CDR2/CDR2L antigens with a MW of
62 kDa. The Yo positive serum also produced several bands, but showed
strong bands in the 62 kDa (CDR2/2L) region (Fig. 2). The HRP conjugat-
ed antibody alone did not stain the blots.
4. Discussion
Neuronal antibodies have previously been reported in sera from
patients with various neuropsychiatric disorders such as autism,
schizophrenia and limbic encephalitis (Laadhar et al., 2015; Mostafa
et al., 2014; Margari et al., 2013; Moscato et al., 2010; Braunschweig
and Van de Water, 2012; Ezeoke et al., 2013; Leypoldt et al., 2015).
However, there are several questions regarding serum antibodies in
neuropsychiatric disorders; why do they arise, do they pass the
blood–brain barrier, are they causative for the disease, are they
apparent only at disease debut or also later in the disease progression,
is the antibody production affected by psychiatric drug treatment etc.
In addition, replication studies are scarce (Dahm et al., 2014; Ezeoke
et al., 2013).
Serum antibodies directed against antigens like Ri (NOVA1 and
NOVA2 genes), Ma2/Ta (PNMA2 gene), CRMP5 (DPYSL5 gene), HuD
(ELAVL4 gene), Yo (CDR2 and CDR2L genes), and amphiphysin (AMPH
gene) are associated with PNS such as encephalomyelitis, limbic
encephalitis, peripheral neuronopathy and cerebellar ataxia. We have
previously shown that themajority of patients with paraneoplastic cer-
ebellar degeneration have Yo antibodies against both CDR2 and CDR2L
proteins (Eichler et al., 2013). The presence of antibodies against the
CDR2 and CDR2L proteins are associatedwith loss of cerebellar Purkinje
cells, probably due to dysregulation of the cell calcium homeostasis
(Schubert et al., 2014).
Recently it was shown that ADHD patients had a high prevalence of
serumYoantibodies (Passarelli et al., 2013). The sera gave a cytoplasmic
staining of the cerebellar Purkinje cells and moderate signals at
Euroimmun Euroline line blots (Neuronal Antigens Proﬁle 2) indicating
the presence of CDR2/Yo antibodies.We found these results unexpected
since Yo antibodies usually are markers of PCD in postmenopausal
women with ovarian or breast cancer (Storstein and Vedeler, 2007).
In this study, we examined 169 adult ADHD patients for the
occurrence of PNS associated antibodies. None of the sera were positive
Fig. 1. Indirect immunoﬂuorescence on cerebellar sections. Sera from two representative ADHD patients (A and B/C) showing positive cytoplasmic Purkinje cell staining at 1:100 dilution,
(A–B) 20× and (C) 60× (serumA corresponds to lane 2 serum, and serum B/C corresponds to lane 3 serum respectively in Fig. 2). (D) Yo antibody positive serum at 1:500 dilution from a
PCD patient (20×), and (E) control serum from a non-ADHD individual (1:100 dilution; 20×). No staining of the Purkinje cell bodies (layer between GL andML)was observed in (E). GL=
granular cell layer, ML =molecular layer.
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following our diagnostic PNS protocol, whereas 1 of the sera revealed
a very weak positive CDR2/Yo band and 9 sera showed borderline
values for CDR2/Yo, amphiphysin and/or Ma2 in the EuroLineScan eval-
uated Euroimmun line blots. The various results from Ravo- and
Euroimmun line blots may be due to the use of different patient sera di-
lutions (1:2000 vs 1:101, respectively), but also to different evaluation
techniques.
We also tested 48 ADHD sera, including the 10 borderline value sera
in the Euroimmun line blot, by indirect immunoﬂuorescence using cer-
ebellum sections. Ten sera showed positive cytoplasmic staining of the
Purkinje cells and could resemble anti-Yo staining, including 7 of the
10 borderline value sera.
The Yo bands of both Ravo Diagnostica and Euroimmun line blots
were based on recombinant CDR2 and not CDR2L, and serum antibodies
against CDR2L cannot be excluded. However, we did not detect Yo anti-
bodies in the 13 ADHD sera tested on cells transfected with either CDR2
or CDR2L. Furthermore, we tested 4 of these sera using Western blot of
cerebellar extract. As expected, the sera reacted with various proteins,
but not with the CDR2/CDR2L proteins (Fig. 2).
In the previous report by Passarelli et al. (2013) sera from 26 of 30
(87%) children with ADHD reacted with Purkinje cells. These results
are not in line with ours where we ﬁnd no evidence for Yo antibodies
in adult ADHD patients. However, we cannot exclude that there may
be a different prevalence of such antibodies in adult and young ADHDpatients. However, this explanation is less likely, as we did not observe
an effect of age on the borderline neuronal antibody levels detected by
the Euroimmun line blot in our 10 patients (age 20–43 years) and
age-dependent decline in antibody levels are not commonly observed
in autoimmune disorders (Manz et al., 2005).
In conclusion, our study did notﬁndneuronal PNS antibodies such as
anti-Yo in sera of adult ADHD patients. However, some of the patients
had antibodies against other proteins in the Purkinje cells. Further stud-
ies are necessary to reveal what proteins these sera react with and the
possible relevance of Purkinje cell antibodies in ADHD. The presence
of low-levels of serum antibodies must be interpreted with caution. If
these antibodies can also be shown intrathecally, this may indicate a
possible association with the disease. However, as such studies are
still lacking for ADHD, it is not possible to conclude that such serum
antibodies have a pathogenic role in this disease.
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Fig. 2.Western blot analysis of rat cerebellum tissue lysate. Lanes 1 through 4 represents
four different ADHD patient sera. Lane 5: serum from a Yo positive PCD patient, lane 6:
control serum from a non-ADHD individual. All sera used at 1:100 dilutions. Only the
PCD patient serum (lane 5) demonstrated strong staining of the Yo antigen (62 kDa band).
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